Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143425 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL1598193 | 0.80 | ALDH1A1 (0.64) | ALDH1A1MAPTL3MBTL1MEN1KMT2A | |
| Formaldehyde SCHEMBL8154204 | 0.80 | ALDH1A1 (0.48) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL3290270 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL11095724 | 0.75 | — | — | |
| SCHEMBL24162936 | 0.75 | ALDH1A1 (0.40) | ALDH1A1GAAHPGDMAPK1 | |
| SCHEMBL5800419 | 0.72 | KDM4E (0.53) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL9886463 | 0.70 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL1728513 | 0.70 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL17254460 | 0.70 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687281-A1 | SYNTHESIS OF 2-CHLORO-3,6-DIALKYL PYRAZINES | Pharmacia & Upjohn Company LLC (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005049583-A1 | SYNTHESIS OF 2-CHLORO-3,6-DIALKYL PYRAZINES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050107610-A1 | Synthesis of 2-chloro-3,6-dialkyl pyrazines | PFIZER INC | 2005-05-19 | — | — | US | claimed |
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | ZYMERGEN INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | ZYMERGEN INC. (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2022006023-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | ZYMERGEN INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-1773484-B1 | FUNCTIONALIZED PARTICLES | HUNTSMAN TEXTILE EFFECTS GER (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-8546509-B2 | Functionalized particles | HUNTSMAN TEXTILE EFFECTS (GERMANY) GMBH (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110077375-A1 | Functionalized particles | HUNTSMAN TEXTILE EFFECTS (GERMANY) GMBH (DE) | 2011-03-31 | — | — | US | disclosed |
| EP-1773484-A1 | FUNCTIONALIZED PARTICLES | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) | 2007-04-18 | — | — | EP | disclosed |
| EP-1687281-A1 | SYNTHESIS OF 2-CHLORO-3,6-DIALKYL PYRAZINES | Pharmacia & Upjohn Company LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1687281-A1 | SYNTHESIS OF 2-CHLORO-3,6-DIALKYL PYRAZINES | Pharmacia & Upjohn Company LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006013165-A1 | FUNCTIONALIZED PARTICLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-02-09 | — | — | WO | disclosed |
| WO-2005049583-A1 | SYNTHESIS OF 2-CHLORO-3,6-DIALKYL PYRAZINES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049583-A1 | SYNTHESIS OF 2-CHLORO-3,6-DIALKYL PYRAZINES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050107610-A1 | Synthesis of 2-chloro-3,6-dialkyl pyrazines | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-20050107610-A1 | Synthesis of 2-chloro-3,6-dialkyl pyrazines | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | HDHD5, HAO2, ALAD | ALDH1A1 2236/4885MAPT 2075/4885L3MBTL1 3051/4885 |
| US-20050107610-A1 | Synthesis of 2-chloro-3,6-dialkyl pyrazines | DCLK2, DCK, PDK2 | ALDH1A1 1831/4885MAPT 3943/4885L3MBTL1 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.